These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21173792)

  • 1. The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.
    Velde NV; Wu EQ; Guo A; Lu M; Yu AP; Sharma H; Liu J; Fan CP; Shi L
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):79-84. PubMed ID: 21173792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events.
    Sherer JT; Adamus AT
    Pharmacotherapy; 2007 Feb; 27(2):207-17. PubMed ID: 17253911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis.
    Izumi K; Mizokami A; Itai S; Shima T; Shigehara K; Miwa S; Maeda Y; Konaka H; Koh E; Namiki M
    BJU Int; 2012 Feb; 109(3):394-400. PubMed ID: 21599822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
    Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
    Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
    Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
    J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
    James ND; Pirrie SJ; Pope AM; Barton D; Andronis L; Goranitis I; Collins S; Daunton A; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Hussain S; Russell M; Billingham LJ
    JAMA Oncol; 2016 Apr; 2(4):493-9. PubMed ID: 26794729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
    Zhao X; Xu X; Guo L; Ragaz J; Guo H; Wu J; Shao Z; Zhu J; Guo X; Chen J; Zhu B; Wang Z; Hu X
    Breast Cancer Res Treat; 2010 Dec; 124(3):733-43. PubMed ID: 20882405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis.
    Hatoum HT; Lin SJ; Smith MR; Guo A; Lipton A
    Clin Breast Cancer; 2011 Jun; 11(3):177-83. PubMed ID: 21665138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
    Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ
    Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.
    Weinfurt KP; Castel LD; Li Y; Timbie JW; Glendenning GA; Schulman KA
    Med Care; 2004 Feb; 42(2):164-75. PubMed ID: 14734954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
    Lipton A; Zheng M; Seaman J
    Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
    Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
    Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
    J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.